Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AflibeRcept or Bevacizumab In Combination With Folfiri as Second-line Treatment of RAS Mutated metastaTIc cOlorectal Cancer patieNts

NCT04397601 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT04397601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04397601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AflibeRcept or Bevacizumab In Combination With Folfiri as Second-line Treatment of RAS Mutated metastaTIc cOlorectal Cancer patieNts
Lead sponsor
National Cancer Institute, Naples
Phase
Observational
Overall status
Unknown status
Start date
May 11, 2020
Completion date
May 11, 2024
Enrollment
220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer